NASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis $16.51 +0.48 (+2.99%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$15.85▼$16.6750-Day Range$11.54▼$16.5152-Week Range$6.13▼$30.96Volume705,040 shsAverage Volume827,757 shsMarket Capitalization$990.10 millionP/E RatioN/ADividend YieldN/APrice Target$29.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunome alerts: Email Address Immunome MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.5% Upside$29.80 Price TargetShort InterestBearish27.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 9 Articles This WeekInsider TradingAcquiring Shares$27,140 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.45) to ($2.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.51 out of 5 starsMedical Sector716th out of 936 stocksPharmaceutical Preparations Industry333rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingImmunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunome has only been the subject of 3 research reports in the past 90 days.Read more about Immunome's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted27.47% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNM. Previous Next 3.2 News and Social Media Coverage News SentimentImmunome has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Immunome this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for IMNM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows5 people have added Immunome to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,140.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Immunome is held by insiders.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunome are expected to decrease in the coming year, from ($1.45) to ($2.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 5.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunome's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Immunome Stock (NASDAQ:IMNM)Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Read More IMNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNM Stock News HeadlinesJuly 25 at 10:52 AM | finance.yahoo.comNectin Therapeutics Licenses Novel Antibodies to ImmunomeJuly 25 at 10:52 AM | finance.yahoo.comImmunome Provides Update on Recent Business Development Activity Expected to Expand ADC CapabilitiesJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…July 19, 2024 | finance.yahoo.comImmunome Insiders Added US$2.67m Of Stock To Their HoldingsJune 27, 2024 | seekingalpha.comImmunome: AL102 And Other Established Protein Targets Could Drive ValueJune 27, 2024 | seekingalpha.comImmunome: Enthusiasm For New Management Has FadedMay 24, 2024 | msn.comImmunome (NASDAQ:IMNM): An Opportunity for Investors with Strong StomachsMay 21, 2024 | finance.yahoo.comInsider Buying: Immunome Inc's CEO Acquires 100,000 SharesJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…May 20, 2024 | businesswire.comImmunome Announces Completion of Purchase of Assets from AtrecaMay 17, 2024 | msn.comImmunome appoints CFOMay 17, 2024 | businesswire.comImmunome Announces Promotion of Max Rosett to Chief Financial OfficerMay 16, 2024 | markets.businessinsider.comImmunome’s Promising Pipeline and Strategic Positioning Affirm Buy RatingMay 14, 2024 | investorplace.comIMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | markets.businessinsider.comImmunome, Inc. Q1 Loss Increases, Misses EstimatesMay 14, 2024 | businesswire.comImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | businesswire.comImmunome to Present at 2024 Bank of America Healthcare ConferenceMay 2, 2024 | businesswire.comImmunome Appoints Kinney Horn as Chief Business OfficerSee More Headlines Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMNM CUSIPN/A CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$29.80 High Stock Price Target$35.00 Low Stock Price Target$24.00 Potential Upside/Downside+79.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($7.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,810,000.00 Net Margins-1,829.44% Pretax Margin-1,829.44% Return on Equity-37.33% Return on Assets-26.06% Debt Debt-to-Equity RatioN/A Current Ratio10.18 Quick Ratio10.18 Sales & Book Value Annual Sales$14.02 million Price / Sales71.05 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book6.00Miscellaneous Outstanding Shares59,970,000Free Float54,812,000Market Cap$996.10 million OptionableOptionable Beta1.79 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Clay B. Siegall Ph.D. (Age 63)President, CEO & Chairman Comp: $1.43MDr. Jack Higgins Ph.D. (Age 44)Chief Scientific Officer Comp: $956.34kDr. Robert J. Lechleider M.D. (Age 63)Chief Medical Officer Comp: $512.49kKey CompetitorsIGM BiosciencesNASDAQ:IGMSVir BiotechnologyNASDAQ:VIRAimmune TherapeuticsNASDAQ:AIMTBiohavenNYSE:BHVNIDEAYA BiosciencesNASDAQ:IDYAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 150,100 shares on 7/26/2024Ownership: 0.250%Clear Creek Financial Management LLCBought 4,035 shares on 7/25/2024Ownership: 0.044%Wealth Enhancement Advisory Services LLCBought 30,617 shares on 7/16/2024Ownership: 0.069%Sequoia Financial Advisors LLCBought 17,065 shares on 7/16/2024Ownership: 0.028%SG Americas Securities LLCBought 90,504 shares on 7/12/2024Ownership: 0.151%View All Insider TransactionsView All Institutional Transactions IMNM Stock Analysis - Frequently Asked Questions How have IMNM shares performed this year? Immunome's stock was trading at $10.70 on January 1st, 2024. Since then, IMNM stock has increased by 54.3% and is now trading at $16.51. View the best growth stocks for 2024 here. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) released its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.46. The company earned $1.03 million during the quarter, compared to analysts' expectations of $4 million. Immunome had a negative net margin of 1,829.44% and a negative trailing twelve-month return on equity of 37.33%. When did Immunome IPO? Immunome (IMNM) raised $30 million in an IPO on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO. Who are Immunome's major shareholders? Top institutional shareholders of Immunome include Bank of New York Mellon Corp (0.25%), SG Americas Securities LLC (0.15%), Wealth Enhancement Advisory Services LLC (0.07%) and Clear Creek Financial Management LLC (0.04%). Insiders that own company stock include Michael Rapp and Bruce Turner. View institutional ownership trends. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
